Literature DB >> 28669032

Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis.

Elena Grebenciucova1, Joseph R Berger2.   

Abstract

PURPOSE OF REVIEW: This review highlights some of the important changes in the immune system that occur in the process of normal aging. Immunosenescence as a concept is directly relevant to the world of neuro-inflammation, as it may be a contributing factor to the risks associated with some of the current immunosuppressive and immunomodulatory therapies used in treating multiple sclerosis (MS) and other inflammatory disorders. RECENT
FINDINGS: Profound qualitative and quantitative changes occur in the adaptive and innate immunity compartments during aging. These changes may explain why patients of older age are at an increased risk of infections and infection-associated mortality. Immunosenescence-associated changes may be additive or synergistic with the effects produced by immunomodulatory and immunosuppressive medications. Clinicians should exercise a high level of vigilance in monitoring the risk of infections in older patients on these treatments.

Entities:  

Keywords:  CNS opportunistic infections; Disease modifying therapy; Immune system; Immunosenescence; Multiple sclerosis; Progressive multifocal leukoencephalopathy

Mesh:

Year:  2017        PMID: 28669032     DOI: 10.1007/s11910-017-0771-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  115 in total

Review 1.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty.

Authors:  W B Ershler; E T Keller
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

2.  Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen.

Authors:  Silvia Ariotti; Joost B Beltman; Grzegorz Chodaczek; Mirjam E Hoekstra; Anna E van Beek; Raquel Gomez-Eerland; Laila Ritsma; Jacco van Rheenen; Athanasius F M Marée; Tomasz Zal; Rob J de Boer; John B A G Haanen; Ton N Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

Review 3.  Immune regulation by CD40 and its ligand GP39.

Authors:  T M Foy; A Aruffo; J Bajorath; J E Buhlmann; R J Noelle
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

4.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

5.  Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell Activation.

Authors:  Guangjin Li; Jihang Ju; Cornelia M Weyand; Jörg J Goronzy
Journal:  J Immunol       Date:  2015-06-19       Impact factor: 5.422

6.  Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging.

Authors:  Yun-Hee Youm; Ryan W Grant; Laura R McCabe; Diana C Albarado; Kim Yen Nguyen; Anthony Ravussin; Paul Pistell; Susan Newman; Renee Carter; Amanda Laque; Heike Münzberg; Clifford J Rosen; Donald K Ingram; J Michael Salbaum; Vishwa Deep Dixit
Journal:  Cell Metab       Date:  2013-10-01       Impact factor: 27.287

7.  The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study.

Authors:  G G Steinmann; B Klaus; H K Müller-Hermelink
Journal:  Scand J Immunol       Date:  1985-11       Impact factor: 3.487

Review 8.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 9.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases.

Authors:  Claudio Franceschi; Judith Campisi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-06       Impact factor: 6.053

10.  Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.

Authors:  Luca Prosperini; Nicola de Rossi; Cristina Scarpazza; Lucia Moiola; Mirco Cosottini; Simonetta Gerevini; Ruggero Capra
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

View more
  15 in total

Review 1.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

2.  Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients.

Authors:  Jeroen Blommaert; Gwen Schroyen; Mathieu Vandenbulcke; Ahmed Radwan; Ann Smeets; Ron Peeters; Charlotte Sleurs; Patrick Neven; Hans Wildiers; Frédéric Amant; Stefan Sunaert; Sabine Deprez
Journal:  Hum Brain Mapp       Date:  2019-08-21       Impact factor: 5.038

Review 3.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

4.  Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Authors:  Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald
Journal:  Mult Scler Relat Disord       Date:  2020-11-23       Impact factor: 4.339

Review 5.  Memory CD4+ T Cells in Immunity and Autoimmune Diseases.

Authors:  Itay Raphael; Rachel R Joern; Thomas G Forsthuber
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

6.  The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis.

Authors:  Roberto De Masi; Stefania Orlando; Antonella De Donno
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-22

Review 7.  Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Authors:  Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-07-06       Impact factor: 5.749

8.  Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis.

Authors:  Carmen Picón; Amalia Tejeda-Velarde; José Ignacio Fernández-Velasco; Manuel Comabella; Roberto Álvarez-Lafuente; Ester Quintana; Susana Sainz de la Maza; Enric Monreal; Noelia Villarrubia; José Carlos Álvarez-Cermeño; María Inmaculada Domínguez-Mozo; Lluís Ramió-Torrentà; Eulalia Rodríguez-Martín; Ernesto Roldán; Yolanda Aladro; Silvia Medina; Mercedes Espiño; Jaime Masjuan; Clara Matute-Blanch; Marta Muñoz-San Martín; Carmen Espejo; Carmen Guaza; Alfonso Muriel; Lucienne Costa-Frossard; Luisa María Villar
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

Review 9.  Targeting senescence to delay progression of multiple sclerosis.

Authors:  Wendy Oost; Nynke Talma; Jan F Meilof; Jon D Laman
Journal:  J Mol Med (Berl)       Date:  2018-09-18       Impact factor: 4.599

10.  Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status.

Authors:  Boris A Kallmann; Stefan Ries; Jennifer S Kullmann; Laura M Quint; Ulrich Engelmann; Andrew Chan
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.